Armistice Capital Holds Stakes in CNS and Cardiovascular Drug Developers Alongside Fellow Institutions

Armistice Capital, which manages more than $7 billion in assets, holds disclosed positions across both central nervous system and cardiovascular drug developers, reflecting a healthcare portfolio that spans multiple therapeutic areas beyond its best-known rare disease holdings. The fund’s 13F filings show activity in Supernus Pharmaceuticals, a neurology-focused company, and Cytokinetics, which is developing cardiovascular medicines, alongside larger positions in rare disease drug developers.

Supernus Pharmaceuticals develops and markets treatments for seizure disorders and maintains a pipeline targeting Parkinson’s disease and other movement conditions. Armistice holds approximately 5.2 million shares of Supernus, representing roughly 2.55% of its disclosed portfolio. Alongside Armistice, Vanguard Group and BlackRock hold positions in Supernus through passive mandates, while Baker Bros. Advisors and RTW Investments represent specialist healthcare fund exposure to the same stock. The company’s combination of marketed products generating revenue and a pipeline of new candidates has attracted a broad range of institutional interest.

Cytokinetics is advancing aficamten, a drug candidate for hypertrophic cardiomyopathy, through late-stage clinical development. Armistice’s position in Cytokinetics includes approximately 1.02 million shares alongside approximately 2.7 million call option contracts, a structure that provides greater leverage to clinical and regulatory outcomes than a pure equity position. T. Rowe Price, Norges Bank, AQR Capital Management, and Deep Track Capital are among the other institutions with disclosed Cytokinetics positions.

The presence of Armistice Capital in both CNS and cardiovascular therapeutic areas alongside its rare disease holdings illustrates how healthcare-focused hedge funds often build portfolios that cut across multiple drug development categories. Vanguard Group and BlackRock provide baseline institutional ownership across these categories through index mandates, while active managers including Armistice, Millennium Management, and Wellington Management add conviction-based positions that reflect their own assessment of clinical and regulatory risk. Together, this mix of institutional ownership types characterizes much of the mid-cap specialty pharmaceutical market.